Tinea Pedis Clinical Trial
Official title:
An Open-Label, Multi-Center, Multiple-Application Pharmacokinetic Study of NAFT-500 in Pediatric Subjects With Tinea Cruris and Tinea Pedis and NAFT-600 in Pediatric Subjects With Tinea Pedis
This study is being done to see how the body is affected when a study drug is applied to both feet if the subject has athlete's foot or to both feet and the groin area if the subject have both athlete's foot and jock itch. Safety of the drug and how well the drug works will also be measured.
Study population, diagnosis, and main criteria for inclusion:
Tinea pedis and Tinea cruris (NAFT-500):
Male or non-pregnant female subjects aged 12 to 17 years, 11 months old of any race with
Tinea pedis and Tinea cruris infections confirmed by a positive KOH analysis from both the
feet and bikini area. Both cases (feet and bikini area) must be characterized by clinical
evidence of a Tinea pedis and Tinea cruris infection. Additional, approximately 4 PK
evaluable adult subjects with the same condition will serve as a control.
Tinea pedis (NAFT-600):
Male or non-pregnant female subjects aged 12 to 17 years, 11 months old of any race with
Tinea pedis infection confirmed by a positive KOH analysis from both feet. Both feet must be
characterized by clinical evidence of a Tinea pedis infection. Additional, approximately 4
PK evaluable adult subjects with the same condition will serve as a control.
;
Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05493488 -
A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Tinea Pedis
|
Phase 2 | |
| Completed |
NCT04883593 -
A Study Comparing the Efficacy of TA103 and the Placebo Control in the Treatment of Interdigital Tinea Pedis.
|
Early Phase 1 | |
| Terminated |
NCT02842021 -
Efficacy and Safety of Product S2G6T-1in Patients With Symptomatic Inflammatory Interdigital Tinea Pedis
|
Phase 2 | |
| Completed |
NCT00781664 -
Cumulative Irritation Test
|
Phase 1 | |
| Completed |
NCT03676686 -
Study With Nåva Foot Cream in Patients With Tinea Pedis Interdigitalis
|
N/A | |
| Completed |
NCT01519752 -
A Therapeutic Equivalence Study of Two Oxiconazole Nitrate Topical Cream Treatments for Patients With Tinea Pedis
|
Phase 1 | |
| Completed |
NCT03320486 -
Non-inferiority Trial of Dapaconazole Versus Ketoconazole
|
Phase 3 | |
| Completed |
NCT01580891 -
Evaluate the Clinical Equivalence of Two Naftifine HCl 1% Creams in Patients With Interdigital Tinea Pedis
|
Phase 1 | |
| Completed |
NCT01353976 -
Safety and Efficacy of Econazole Nitrate Foam 1% in Subjects With Tinea Pedis
|
Phase 3 | |
| Completed |
NCT01349998 -
Safety of a Topical Antifungal Treatment for Tinea Cruris, Tinea Pedis and Tinea Corporis
|
Phase 3 | |
| Completed |
NCT04265521 -
Study With BioCool Footcare in Subjects With Tinea Pedis Interdigitalis and Heel Cracks, Calluses and/or Dry Feet
|
N/A | |
| Completed |
NCT02633813 -
BE Study of Naftifine HCL
|
Phase 3 | |
| Recruiting |
NCT00856596 -
Once a Day Topical Treatment for Athlete's Foot Fungus Inbetween the Toes in Males and Females
|
Phase 3 | |
| Completed |
NCT00869336 -
Multicenter Study of the Efficacy and Safety of Luliconazole Cream in Tinea Pedis (Athlete's Foot)
|
Phase 2 | |
| Completed |
NCT00768599 -
A Study of Econazole Foam 1% in Athlete's Foot
|
Phase 2 | |
| Recruiting |
NCT00233493 -
Spread of Dermatophytes Among Families
|
N/A | |
| Completed |
NCT03897257 -
A Comparison Study of UHE-103 Cream in Subjects With Moccasin Type Tinea Pedis
|
Phase 2 | |
| Completed |
NCT03129321 -
Therapeutic Equivalence and Safety of Two Econazole Nitrate Cream, 1% Products in Tinea Pedis
|
Phase 3 | |
| Completed |
NCT02335255 -
Evaluate Safety and Efficacy of Naftifine Hydrochloride Gel 2% and Naftin® Gel 2% in Tinea Pedis
|
Phase 1 | |
| Withdrawn |
NCT02606383 -
Non-inferiority Phase III Trial Comparing Dapaconazole Cream 2% With Ketoconazole Cream 2% in Patients With Tinea Pedis
|
Phase 3 |